OM1 expands into Europe to enhance AI-driven real-world evidence solutions

OM1 is expanding into Europe to meet the growing demand for AI-powered real-world evidence (RWE) solutions, supporting healthcare and life sciences organizations in drug development, market access, and regulatory decision-making.

OM1, a provider of real-world data (RWD) and AI-driven insights for life sciences, has announced plans to expand into Europe. This move aims to support pharmaceutical and healthcare organizations by offering AI-enhanced RWE solutions, addressing the growing demand for validated data and observational research in drug development, market access, and regulatory decision-making.

The move builds on OM’s current operations in the US market and is driven by increasing demand for AI-powered RWD to support clinical and commercial strategies. By establishing a stronger presence in Europe, OM1 will collaborate with healthcare institutions, regulatory bodies, and biopharmaceutical companies to further develop RWE capabilities.

“OM1 has consistently been at the forefront of using AI to enrich real-world data and deliver meaningful, patient-centered insights,” said Dr. Richard Gliklich, CEO and Founder of OM1. “Expanding into Europe allows us to better serve our global customers by enabling them to generate critical real-world insights that improve patient outcomes and drive commercial success”. 

Glicklich shared his insights on the expanding role of RWE in a recent episode of Patti’s People on The Evidence Base. 

OM1’s technology platforms will support its work in Europe. The OM1 Aspen platform will facilitate data collection and analysis for both clinical and commercial applications, supporting prospective and retrospective studies as well as patient registries. In addition, OM1’s AI-powered digital phenotyping platform, PhenOM®, will help life sciences organizations gain deeper insights into disease patterns, refine clinical development, and navigate regulatory and market access requirements.

“With the increasing demand for AI-driven real-world evidence solutions across Europe, OM1 is well-positioned to support life sciences organizations in navigating evolving regulatory frameworks and advancing research and commercialization,” said Eric Mertz, General Manager of OM1 Europe. “This expansion allows us to deliver tailored, region-specific solutions that offer greater insights and contribute to improved patient outcomes.”